A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin

Youn Ho Kim, Woo Sik Han, Sun Jae Lee, Sung Nam Oh, Do Won Choi, Kwan Soo Byun, Jong Eun Yeon

Research output: Contribution to journalArticle

Abstract

There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.

Original languageEnglish
Pages (from-to)419-422
Number of pages4
JournalThe Korean journal of hepatology
Volume13
Issue number3
DOIs
Publication statusPublished - 2007 Sep 1

Fingerprint

Ribavirin
Chronic Hepatitis C
Vasculitis
Interferons
Hemolytic Anemia
Antiviral Agents
Therapeutics
Bone Marrow
peginterferon alfa-2a

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin. / Kim, Youn Ho; Han, Woo Sik; Lee, Sun Jae; Oh, Sung Nam; Choi, Do Won; Byun, Kwan Soo; Yeon, Jong Eun.

In: The Korean journal of hepatology, Vol. 13, No. 3, 01.09.2007, p. 419-422.

Research output: Contribution to journalArticle

Kim, Youn Ho ; Han, Woo Sik ; Lee, Sun Jae ; Oh, Sung Nam ; Choi, Do Won ; Byun, Kwan Soo ; Yeon, Jong Eun. / A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin. In: The Korean journal of hepatology. 2007 ; Vol. 13, No. 3. pp. 419-422.
@article{4effec448af74326ac7a7de001a90c9d,
title = "A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin",
abstract = "There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.",
author = "Kim, {Youn Ho} and Han, {Woo Sik} and Lee, {Sun Jae} and Oh, {Sung Nam} and Choi, {Do Won} and Byun, {Kwan Soo} and Yeon, {Jong Eun}",
year = "2007",
month = "9",
day = "1",
doi = "10.3350/kjhep.2007.13.3.419",
language = "English",
volume = "13",
pages = "419--422",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "3",

}

TY - JOUR

T1 - A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin

AU - Kim, Youn Ho

AU - Han, Woo Sik

AU - Lee, Sun Jae

AU - Oh, Sung Nam

AU - Choi, Do Won

AU - Byun, Kwan Soo

AU - Yeon, Jong Eun

PY - 2007/9/1

Y1 - 2007/9/1

N2 - There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.

AB - There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.

UR - http://www.scopus.com/inward/record.url?scp=58149087841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149087841&partnerID=8YFLogxK

U2 - 10.3350/kjhep.2007.13.3.419

DO - 10.3350/kjhep.2007.13.3.419

M3 - Article

VL - 13

SP - 419

EP - 422

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 3

ER -